MedTrace Logo

Dexmedetomidine Improves the Surgical Field and Postoperative Recovery of Nasal Endoscopic Surgery

NCT04276545 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2020-03-16

No results posted yet for this study

Summary

Studies showed dexmedetomidine (DEX) could improve surgical field, but the effect for functional nasal endoscopic surgery (FESS) was unclear. The investigators explored IV administration of a single loading dose DEX (0.5μg/kg) for FESS, and IV administration of midazolam (0.05mg/kg) as a control with comparision of surgical field, haemodynamics, ventilation parameters and recovery.

Conditions

  • Dexmedetomidine
  • Bleeding
  • Surgical Field

Interventions

DRUG

IV administration of DEX to investigate the effects for functional nasal endoscopic surgery

IV administration of a single loading dose DEX (0.5μg/kg) after induction within 10 minutes.

DRUG

IV administration of Midazolam to investigate the effects for functional nasal endoscopic surgery

IV administration of midazolam (0.05mg/kg) after induction.

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Shenghai Zhang · Eye, Ear, Nose and Throat Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-03-10
Completion
2020-03-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04276545 on ClinicalTrials.gov